Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.
Biomarker and diagnostic research for membranous glomerulonephritis has been reported in the published literature.
No approved treatments are currently available for membranous glomerulonephritis. An additional 8 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for membranous glomerulonephritis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for membranous glomerulonephritis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
63 clinical trials registered, 28 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 4 PHASE4, 7 PHASE3, 20 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07404436](https://clinicaltrials.gov/study/NCT07404436) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 9:38 PM UTC
Designated
Exclusivity End |
|---|
Designation Status |
|---|
povetacicept | povetacicept | Vertex Pharmaceuticals Incorporated | 2026 | — | Designated |
zanubrutinib | zanubrutinib | BeOne Medicines USA, Inc. | 2024 | — | Designated |
Corticotropin (ACTH) porcine (synthetic) | Corticotropin (ACTH) porcine (synthetic) | Cerium Pharmaceuticals, Inc. | 2023 | — | Designated |
felzartamab | felzartamab | Human Immunology Biosciences | 2023 | — | Designated |
rituximab | rituximab | Mabion S.A. | 2023 | — | Designated |
Budoprutug | Budoprutug | Climb Bio, Inc. | 2023 | — | Designated |
Mizoribine | Mizoribine | RNR BioMedical Inc. | 2020 | — | Designated |
obinutuzumab | obinutuzumab | Genentech, Inc., A Member of the Roche Group | 2020 | — | Designated |
felzartamab is referenced in active clinical trials for membranous glomerulonephritis (designated 2023).
rituximab is referenced in active clinical trials for membranous glomerulonephritis (designated 2023).
63 trials found
Rivaroxaban in Idiopathic Membranous Nephropathy |
PHASE4 |
Beijing Friendship Hospital |
RECRUITING |
[NCT06893328](https://clinicaltrials.gov/study/NCT06893328) | A Real World Study About PMN | — | Wei Chen | RECRUITING |
[NCT07038382](https://clinicaltrials.gov/study/NCT07038382) | A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis | PHASE2 | Shanghai Henlius Biotech | RECRUITING |
[NCT06557265](https://clinicaltrials.gov/study/NCT06557265) | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | PHASE1 | Nkarta, Inc. | RECRUITING |
[NCT06341205](https://clinicaltrials.gov/study/NCT06341205) | Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) | PHASE3 | Centre Hospitalier Universitaire de Nice | RECRUITING |
148 publications have been identified in PubMed for membranous glomerulonephritis. Kisho has analyzed 104 by research type. Research spans Review / Meta-Analysis (31%), Case Report / Case Series (17%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 32 | 31% |
Patient case studies | 18 | 17% |
Laboratory research | 18 | 17% |
Disease patterns and progression | 12 | 12% |
Clinical study results | 10 | 10% |
Testing and diagnosis research | 9 | 9% |
Other research | 5 | 5% |
Leto J (2026). [PMID: 41015758](https://pubmed.ncbi.nlm.nih.gov/41015758/). *Pathology*. [Diagnostic / Biomarker]
Nasr SH (2026). [PMID: 41197955](https://pubmed.ncbi.nlm.nih.gov/41197955/). *Kidney Int*. [Clinical Trial Publication]
Constantin MG (2026). [PMID: 42217547](https://pubmed.ncbi.nlm.nih.gov/42217547/). *Lab Invest*. [Diagnostic / Biomarker]
Alok A (2026). [PMID: 32644595](https://pubmed.ncbi.nlm.nih.gov/32644595/). *Unknown Journal*. [Clinical Trial Publication]
Intas K (2026). [PMID: 41811689](https://pubmed.ncbi.nlm.nih.gov/41811689/). *Nephrol Ther*. [Diagnostic / Biomarker]
Alotaibi ME (2026). [PMID: 42040535](https://pubmed.ncbi.nlm.nih.gov/42040535/). *Int J Nephrol*. [Review / Meta-Analysis]
Deeb N (2026). [PMID: 41582224](https://pubmed.ncbi.nlm.nih.gov/41582224/). *Allergy Asthma Clin Immunol*. [Case Report / Case Series]
El Kaoua O (2026). [PMID: 41869110](https://pubmed.ncbi.nlm.nih.gov/41869110/). *Cureus*. [Case Report / Case Series]
Zhang M (2026). [PMID: 41822057](https://pubmed.ncbi.nlm.nih.gov/41822057/). *Clin Kidney J*. [Review / Meta-Analysis]
Kim YK (2026). [PMID: 41809873](https://pubmed.ncbi.nlm.nih.gov/41809873/). *World J Gastroenterol*. [Case Report / Case Series]